Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 2/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685319 | 0.89 | JAK2 (0.36) | MAPKAPK5PTK2IKBKBAURKA | |
| SCHEMBL1685332 | 0.83 | MAPKAPK5 (0.51) | MAPKAPK5 | |
| SCHEMBL3868797 | 0.83 | AURKA (0.49) | MAPKAPK5CCNE1CDK2IKBKBAURKA | |
| SCHEMBL3875479 | 0.82 | TNIK (0.38) | MAPKAPK5 | |
| SCHEMBL1685127 | 0.80 | MAPKAPK5 (0.55) | MAPKAPK5 | |
| SCHEMBL3875061 | 0.79 | MAPKAPK5 (0.36) | MAPKAPK5 | |
| SCHEMBL1685204 | 0.76 | RIPK1 (0.43) | MAPKAPK5CCNE1CDK2 | |
| SCHEMBL3868547 | 0.76 | MAPKAPK5 (0.34) | MAPKAPK5 | |
| SCHEMBL1685173 | 0.75 | MKNK1 (0.43) | IKBKB | |
| SCHEMBL1685151 | 0.75 | CCND1 (0.39) | MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885PTK2 71/4885NAMPT 526/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885PTK2 71/4885NAMPT 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.